Patent search ap:"KUMAMOTO HEALTH SCIENCE UNIVERSITY" Page 2

11.

发明专利
１，３，４－噁二唑－２－羧醯胺有权
Simplified title: １，３，４－恶二唑－２－羧酰胺

公开(公告)号：TWI523851B

公开(公告)日：2016-03-01

申请号：TW099146436

申请日：2010-12-28

Applicant: 養樂多本社股份有限公司 , KABUSHIKI KAISHA YAKULT HONSHA , 一般社團法人藥谷項目支援機構 , SHIZUOKA PREFECTURE , 靜岡縣 , SHIZUOKA PREFECTURE , 學校法人銀杏學園熊本保健科學大學 , KUMAMOTO HEALTH SCIENCE UNIVERSITY

Inventor： 淺井章良 , ASAI, AKIRA , 松野研司 , MATSUNO, KENJI , 小鄉尚久 , OGO, NAOHISA , 高橋理 , TAKAHASHI, OSAMU , 增田吉昭 , MASUDA, YOSHIAKI , 室谷步 , MUROYA, AYUMU , 秋山靖人 , AKIYAMA, YASUTO , 蘆澤忠 , ASHIZAWA, TADASHI , 大川原正 , OKAWARA, TADASHI

IPC: C07D413/04 , C07D413/14 , C07D513/04 , A61K31/4245 , A61K31/4353 , A61K31/429 , A61P35/00

CPC classification number: C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/04 , C07D513/04

12.

发明申请
Therapeutic Agent for Type 2 Diabetes 审中-公开
Title translation: 2型糖尿病治疗剂

公开(公告)号：US20160060235A1

公开(公告)日：2016-03-03

申请号：US14780052

申请日：2014-03-28

Applicant: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY , KUMAMOTO HEALTH SCIENCE UNIVERSITY

Inventor： Kazuhito Tomizawa , Fanyan Wei , Kengo Inoue , Tadashi Okawara

IPC: C07D295/108 , C07D211/58

CPC classification number: C07D295/108 , A61K31/192 , A61K31/197 , A61K31/4545 , A61K31/495 , A61K31/496 , A61K45/06 , C07D211/58 , C07D215/48 , C07D295/15 , C07D295/185 , C07D333/20 , Y02A50/473 , A61K2300/00

Abstract: An object of the present invention is to provide a novel therapeutic agent for a patient with type 2 diabetes, a cause of which is the abnormal synthesis of insulin attributed to the abnormal modification of tRNALys (UUU) in pancreatic β cells having Cdkal1 gene mutation. The present inventors have used (1) a screening system using E. coli in which correct translation into luciferase requires frameshift resulting from mistranslation during protein translation, (2) a screening system using the pancreatic islet of Langerhans isolated from a pancreatic β cell-specific Cdkal1-deficient mouse, and (3) a screening system using a pancreatic β cell-specific Cdkal1-deficient mouse, and found that a compound represented by any of the following formulas (I) to (III) can serve as a therapeutic agent for a patient with type 2 diabetes with Cdkal1 gene mutation resulting in the reduced ability to secrete insulin.

Abstract translation: 本发明的目的是提供一种用于2型糖尿病患者的新型治疗剂，其原因是由于胰腺中tRNALys（UUU）的异常修饰引起的胰岛异常合成; 细胞具有Cdkal1基因突变。本发明人已经使用（1）使用大肠杆菌的筛选系统，其中正确翻译成荧光素酶需要在蛋白质翻译过程中由于错译造成的移码，（2）使用从胰腺分离的朗格汉斯胰岛的筛选系统; 细胞特异性Cdkal1缺陷小鼠，和（3）使用胰腺的筛选系统; 细胞特异性Cdkal1缺陷小鼠，发现由下式（I）至（III）中任一项表示的化合物可用作具有Cdkal1基因突变的2型糖尿病患者的治疗剂，导致其降低的能力分泌胰岛素

13.

发明公开
STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT 有权
Title translation: STAT3抑制剂，含有作为活性成分的羧甲基羧酸酰胺衍生物

公开(公告)号：EP2325181A4

公开(公告)日：2012-03-07

申请号：EP09794208

申请日：2009-07-10

Applicant: PHARMA IP GENERAL INC ASS , PHARMA DESIGN INC , SHIZUOKA PREFECTURE , KUMAMOTO HEALTH SCIENCE UNIVERSITY , YAKULT HONSHA KK

Inventor： ASAI AKIRA , MATSUNO KENJI , OGO NAOHISA , YOKOTAGAWA TAKANE , TAKAHASHI OSAMU , AKIYAMA YASUTO , ASHIZAWA TADASHI , OKAWARA TADASHI

IPC: C07D401/12 , A61K31/4709 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14

CPC classification number: C07D401/12 , A61K31/4709 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14

14.

发明授权
1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND 有权
Title translation: -1,3,4-恶二唑-2-甲酰胺CONNECTION

公开(公告)号：EP2520575B1

公开(公告)日：2016-11-30

申请号：EP10841060.6

申请日：2010-12-28

Applicant: General Incorporated Association Pharma Valley Project Supporting Organization , Shizuoka Prefecture , Kumamoto Health Science University , Kabushiki Kaisha Yakult Honsha

Inventor： ASAI, Akira , MATSUNO, Kenji , OGO, Naohisa , TAKAHASHI, Osamu , MASUDA, Yoshiaki , MUROYA, Ayumu , AKIYAMA, Yasuto , ASHIZAWA, Tadashi , OKAWARA, Tadashi

IPC: C07D413/04 , A61K31/4245 , A61K31/428 , A61K31/437 , A61K31/4439 , A61K31/4545 , A61K31/55 , A61P35/00 , A61P43/00 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/04 , C07D513/04

CPC classification number: C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/04 , C07D513/04

15.

发明公开
1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND 有权
Title translation: -1,3,4-恶二唑-2-甲酰胺，VERBINDUNG

公开(公告)号：EP2520575A1

公开(公告)日：2012-11-07

申请号：EP10841060.6

申请日：2010-12-28

Applicant: General Incorporated Association Pharma Valley Project Supporting Organisation , Pharma Design Inc. , Shizuoka Prefecture , Kumamoto Health Science University , Kabushiki Kaisha Yakult Honsha

Inventor： ASAI, Akira , MATSUNO, Kenji , OGO, Naohisa , TAKAHASHI, Osamu , MASUDA, Yoshiaki , MUROYA, Ayumu , AKIYAMA, Yasuto , ASHIZAWA, Tadashi , OKAWARA, Tadashi

IPC: C07D413/04 , A61K31/4245 , A61K31/428 , A61K31/437 , A61K31/4439 , A61K31/4545 , A61K31/55 , A61P35/00 , A61P43/00 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/04 , C07D513/04

CPC classification number: C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/04 , C07D513/04

Abstract: Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R 1 represents a hydrogen atom or the like; and -X-Y represents a diaryl group such as a biphenyl group).

Abstract translation: 提供具有STAT3抑制活性并可用作抗癌剂的1,3,4-恶二唑-2-甲酰胺化合物。提供由式（I）表示的1,3,4-恶二唑-2-甲酰胺化合物或其药学上可接受的盐（在该式中，Ar表示呋喃基等; R 1表示氢原子等 ; -XY表示二芳基如联苯基）。

16.

发明公开
PLASMA PROTEIN HAVING ANTITUSSIVE EFFECT 有权
Title translation: FXIa MIT HUSTENLINDERNDER WIRKUNG

公开(公告)号：EP2462942A1

公开(公告)日：2012-06-13

申请号：EP10806533.5

申请日：2010-08-05

Applicant: The Chemo-Sero-Therapeutic Research Institute , National University Corporation Kumamoto University , Ginkyo Academy Kumamoto Health Science University

Inventor： KAMEI, Shintaro , SHINDOME, Asami , HAMAMOTO, Takayoshi , MAEDA, Hiroaki , HIRASHIMA,Masaki , OKUDA, Sachio , UMEHASHI, Misako , OGAWA, Sachie , IMUTA, Megumi , AKAIKE, Norio , TAKAHAMA, Kazuo , WADA, Ryoko

IPC: A61K38/00 , A61P11/00 , A61P11/14

CPC classification number: C12N9/6443 , A61K38/4846

Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as "FXIa"), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.

Abstract translation: 提供活化因子XI作为由气管分叉如慢性咳嗽引起的咳嗽的镇咳药。一种用于预防，治疗和/或症状改善咳嗽的药物组合物，其包含多肽链作为活性成分和药学上可接受的载体，其中所述多肽链由构成活化因子XI的全长氨基酸序列组成（以下也称为作为“FXIa”），其中具有一个或几个氨基酸的氨基酸序列被缺失，取代或加入，或任一上述氨基酸序列的部分序列，或包含上述任何一种的氨基酸序列氨基酸序列。

17.

发明公开
STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT 有权
Title translation: 含有喹啉羧酰胺衍生物作为活性成分的STAT3抑制剂

公开(公告)号：EP2325181A1

公开(公告)日：2011-05-25

申请号：EP09794208.0

申请日：2009-07-10

Applicant: Pharma Ip General Incorporated Association , Pharma Design Inc. , Shizuoka Prefecture , Kumamoto Health Science University , Kabushiki Kaisha Yakult Honsha

Inventor： ASAI, Akira , MATSUNO, Kenji , OGO, Naohisa , YOKOTAGAWA, Takane , TAKAHASHI, Osamu , AKIYAMA, Yasuto , ASHIZAWA, Tadashi , OKAWARA, Tadashi

IPC: C07D401/12 , A61K31/4709 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14

CPC classification number: C07D401/12 , A61K31/4709 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14

Abstract: The present invention provides a STAT3 inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR 34 ; and R 1 to R 8 and R 34 each represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like.), or a pharmacologically acceptable salt thereof.

Abstract translation: 本发明提供含有式（I）所示的喹啉甲酰胺衍生物（式中，W表示键或亚烷基链，X表示O，S或NR 34，且R 1〜和R34各自表示H，卤素，烷基，苯基，呋喃基，噻吩基等）或其药理学上可接受的盐。